UBS Global Life Sciences Conference New York, September 2006 Dr Roland Scollay, PhD CEO & Managing Director Metabolic Pharmaceuticals Limited. Forward-looking statement.
New York, September 2006
Dr Roland Scollay, PhD
CEO & Managing Director
Metabolic Pharmaceuticals Limited
This presentation contains forward-looking statements regarding the Company’s business and the therapeutic and commercial potential of its technologies and products in development. Any statement describing the Company’s goals, expectations, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the process of discovering, developing and commercialising drugs that can be proven to be safe and effective for use as human therapeutics, and in the endeavor of building a business around such products and services.
Actual results could differ materially from those discussed in this presentation. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the Metabolic Pharmaceuticals Limited Annual Report for the year ended June 30, 2006, copies of which are available from the Company or at www.metabolic.com.au.
AOD9604 has already been through Phase 1 safety studies in the context of the obesity program.
50:50 Collaboration with Neuren Pharmaceuticals Limited
Metabolic’s drugs target high-value, growing markets with unmet needs:
Board of Directors
Dr Arthur Emmett, Chairman: Medical background, 30 years of drug development experience in big pharma.
Dr Evert Vos, Non-Executive Director: Extensive experience in medical and regulatory affairs.
Ms Robyn Baker, Non-Executive Director: Corporate lawyer specialising in life sciences sector.
Mr Patrick Sutch, Non-Executive Director: Ex-NASDAQ executive with experience in global financial markets.
Metabolic will continue to search externally for additional, high-quality drugs to add to its clinical and preclinical pipelines
Q306 Neuropathic pain drug, ACV1 – Phase 2A program commences (the first of two trials commence)
Q406Obesity drug, AOD9604 – the Phase 2B OPTIONS Study ends (last patient completes the trial in December 2006)
Q107Obesity drug, AOD9604 – Results of the Phase 2B OPTIONS Study expected to be announced in March 2007
H107Neuropathic pain drug, ACV1 – Results of the first of two trials in the Phase 2A program expected to be announced
Other milestones to monitor during 2007:
Metabolic’s innovative obesity drug
(anterior pituitary, 190 AA)
(Synthetic, 16 AA)
Time in weeks
KilogramsPhase 2 results show efficacy at lowest dose
*Not all statistically significant in this trial with low patient numbers. Trial not powered for these comparisons.
An additional use for AOD9604 in a US$7 billion market …
Two current animal studies in progress to determine:
Normal human bone
(Right: Photographs courtesy of Osteoporosis Australia)
Metabolic’s innovative pain drug
Other major world drugs: 2005 global sales (US$)
The current market for obesity prescription drugs is held back by the safety & tolerability issues with existing drugs on the market.
Founding shareholders 23.5%
Retail shareholders 46.4%
Institutions and large private investors (Australia) 23.4%
Institutions and large private investors (Offshore) 6.7%